Publication

Co-Pathological Connected Primary Neurons in a Microfluidic Device for Alzheimer Studies

Abstract

This communication presents a novel experi- mental model for Alzheimer studies, where connected pri- mary neurons were set into subtend, co-pathological states. Cortical neurons were cultured in two separated cell com- partments in a microfluidic device. A neurite network was generated in a main channel through the neurite outgrowth from both cell compartments. A gradient of okadaic acid (OA) is generated over this neurite network by perfusion. OA is a phosphatase inhibitor that induces hyperphosphor- ylation of Tau proteins, a major hallmark in Alzheimer disease. The local OA treatment resulted in a connected ‘‘diseased’’ and ‘‘healthy’’ cell population. Anti-phosphory- lated tau (Ser262) staining confirmed different states of phosphorylated Tau proteins, and synapthophysin staining the connection of ‘‘healthy’’ and ‘‘diseased’’ cells. Here, we present a novel in vitro model that opens the possibility to study cellular and molecular propagation mechanisms in neurodegeneration, in Tauopathies (as e.g., in Alzheimer), as well as simultaneous drug effects on connected healthy and diseased cell populations.

About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.